These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 38876044)

  • 41. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
    Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
    Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y; van der Meel R; Chen X; Lammers T
    Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dendritic Polymer-Based Nanomedicines Remodel the Tumor Stroma: Improve Drug Penetration and Enhance Antitumor Immune Response.
    Zhang Y; Fang Z; Pan D; Li Y; Zhou J; Chen H; Li Z; Zhu M; Li C; Qin L; Ren X; Gong Q; Luo K
    Adv Mater; 2024 Jun; 36(25):e2401304. PubMed ID: 38469918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.
    Swetha KL; Roy A
    Drug Deliv Transl Res; 2018 Oct; 8(5):1508-1526. PubMed ID: 30128797
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics.
    Overchuk M; Zheng G
    Biomaterials; 2018 Feb; 156():217-237. PubMed ID: 29207323
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
    Qin SY; Zhang AQ; Zhang XZ
    Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nanomedicine and chemotherapeutics drug delivery: challenges and opportunities.
    Nezhadi S; Saadat E; Handali S; Dorkoosh F
    J Drug Target; 2021 Feb; 29(2):185-198. PubMed ID: 32772739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma.
    Liu Y; Zhou J; Li Q; Li L; Jia Y; Geng F; Zhou J; Yin T
    Adv Drug Deliv Rev; 2021 May; 172():80-103. PubMed ID: 33705874
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery.
    Cao Z; Li D; Zhao L; Liu M; Ma P; Luo Y; Yang X
    Nat Commun; 2022 Apr; 13(1):2038. PubMed ID: 35440570
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Barrier permeation and improved nanomedicine delivery in tumor microenvironments.
    Liu J; Zhang J; Gao Y; Jiang Y; Guan Z; Xie Y; Hu J; Chen J
    Cancer Lett; 2023 May; 562():216166. PubMed ID: 37028698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
    Qin M; Xia H; Xu W; Chen B; Wang Y
    Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of cancer-associated fibroblasts by nanodelivery system to enhance efficacy of tumor therapy.
    Ai W; Liu T; Lv C; Feng X; Wang Q
    Nanomedicine (Lond); 2023 Jun; 18(15):1025-1039. PubMed ID: 37584613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanism Investigation of Hyaluronidase-Combined Multistage Nanoparticles for Solid Tumor Penetration and Antitumor Effect.
    Chen E; Han S; Song B; Xu L; Yuan H; Liang M; Sun Y
    Int J Nanomedicine; 2020; 15():6311-6324. PubMed ID: 32922003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biological rationale for the design of polymeric anti-cancer nanomedicines.
    Zhou Y; Kopeček J
    J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hydroxyethyl starch-folic acid conjugates stabilized theranostic nanoparticles for cancer therapy.
    Wang C; Wang Q; Wang H; Li Z; Chen J; Zhang Z; Zeng H; Yu X; Yang X; Yang X; Li Z
    J Control Release; 2023 Jan; 353():391-410. PubMed ID: 36473606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy.
    Yang S; Gao H
    Pharmacol Res; 2017 Dec; 126():97-108. PubMed ID: 28501517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.